Top brand choice
Strength | Pack Size | Qty | |
---|---|---|---|
Strength
1092MG/3.5ml
|
|||
Strength
1560MG/5ml
|
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Invega Hafyera (paliperidone palmitate) extended-release injectable suspension is administered every 6 months to treat adults who have schizophrenia following a minimum of 4 months of treatment with once-monthly paliperidone palmitate extended-release injectable suspension (Invega Sustenna®) or Invega Trinza® for a minimum of one 3-month cycle.
Invega Hafyera comes as an extended-release injectable suspension in single-dose, prefilled syringes in strengths of 1,092 mg/3.5 mL or 1,560 mg/5 mL.
Fact Table | |
---|---|
Formula | C39H57FN4O4 |
License | FDA approved |
Bioavailability | Not applicable (intramuscular administration) |
Legal status | Prescription only |
Chemical Name | Paliperidone palmitate |
Elimination half-life | 25 to 49 days (dose-dependent) |
Dosage (Strength) | 1,092 mg every 6 months |
Pregnancy | Consult a healthcare provider |
Brands | Invega Hafyera, Invega Sustenna, Invega Trinza |
Protein binding | 74% |
PubChem CID | 11304729 |
MedlinePlus | a607005 |
ChEBI | 85988 |
ATC code | N05AX13 |
DrugBank | DB06719 |
KEGG | D05340 |
Routes of administration | Intramuscular |
Your doctor will decide on your Invega Hafyera dosage and duration of treatment. The medication will be administered into the muscle of the gluteal region by a healthcare provider.
Do not hesitate to reach out to your doctor with any questions or concerns about your treatment.
Paliperidone palmitate is the active ingredient in Invega Hafyera.
Polysorbate 20, polyethylene glycol 4000, citric acid monohydrate, sodium dihydrogen phosphate monohydrate, sodium hydroxide, and water for injection are the inactive ingredients included.
Invega Hafyera should not be administered to patients who are allergic to risperidone or to any of the active or inactive ingredients or excipients in Invega Hafyera.
Invega Halfyera is associated with the following FDA Boxed Warning:
Invega Hafyera side effects include but are not limited to injection site reaction, upper respiratory tract infection, headache, weight gain, and parkinsonism. Call your doctor right away if you develop bothersome or persistent side effects.
Discuss Invega Hafyera with your doctor and whether it may be appropriate for you.
Invega Hafyera. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2021.